Novo Nordisk reported Phase 3 progress for etavopivat in sickle cell disease, saying the oral drug reduced the occurrence of pain crises and improved hemoglobin response. The company also said it met the goals defined for the late-stage study, though data arrived behind expectations in some respects. The report positions etavopivat as a potential oral alternative in a field where dosing convenience and safety/tolerability remain central tradeoffs. Novo’s update is likely to influence how clinicians and payers compare etavopivat against existing disease-modifying options. Separately, another Novo-linked development highlighted the company’s plans to submit a sickle cell drug to the FDA after a Phase 3 win, signaling sustained late-stage focus in rare hematology.